A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups

Blood

Volumn 113, Issue 1, 2009, Pages 100-107

  Sulong, Sarina ^a   Moorman, Anthony V ^a,b   Irving, Julie A E ^a   Strefford, Jonathan C ^b,c   Konn, Zoe J ^b   Case, Marian C ^a   Minto, Lynne ^a   Barber, Kerry E ^b   Parker, Helen ^b,c   Wright, Sarah L ^b   Stewart, Adam R M ^b   Bailey, Simon ^d   Bown, Nick P ^e   Hall, Andrew G ^a   Harrison, Christine J ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Leukaemia Research Cytogenetics Group   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR RUNX1; HUMAN GROWTH HORMONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B LYMPHOCYTE; CDKN2A GENE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME 11Q23; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY LOSS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METHYLATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; MUTATION; PATHOLOGY; PHENOTYPE; TUMOR SUPPRESSOR GENE;

CHILD; DNA METHYLATION; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P16; GENOMICS; HUMAN GROWTH HORMONE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; LOSS OF HETEROZYGOSITY; MALE; MUTATION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 59449093453     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-166801     Document Type: Article

References (58)

1. Ruas M, Peters G. The p16(INK4a)/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378:F115-F177.
2. Sandal T. Molecular aspects of the mammalian cell cycle and cancer. Oncologist. 2002;7:73-81.
3. Drexler HG. Review of alterations of the cyclindependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
4. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002;21:3475-3495.
5. Baccichet A, Qualman SK, Sinnett D. Allelic loss in childhood acute lymphoblastic leukemia. Leukemia Res. 1997;21:817-823.
6. Takeuchi S, Koike M, Seriu T, et al. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis. Leukemia. 1997;11:1636-1640.
7. Takeuchi S, Tsukasaki K, Bartram CR, et al. Long-term study of the clinical significance of loss of heterozygosity in childhood acute lymphoblastic leukemia. Leukemia. 2003;17:149-154.
8. Irving JA, Bloodworth L, Bown NP, Case MC, Hogarth LA, Hall AG. Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis. Cancer Res. 2005;65: 3053-3058.
9. Komuro H, Valentine MB, Rubnitz JE, et al. p27KIP1 deletions in childhood acute lymphoblastic leukemia. Neoplasia. 1999;1:253-261.
10. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A. 2001;98:11563-11568.
11. Chapman EJ, Harnden P, Chambers P, Johnston C, Knowles MA. Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res. 2005;11:5740-5747.
12. Ohnishi H, Kawamura M, Ida K, et al. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood. 1995;86: 1269-1275.
13. Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cave H. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2003;37:44-57.
14. Iravani M, Dhat R, Price CM. Methylation of the multi tumor suppressor gene-2 (MTS2, CDKN1, p15INK4B) in childhood acute lymphoblastic leukemia. Oncogene. 1997;15:2609-2614.
15. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942-1949.
16. Gutierrez MI, Siraj AK, Bhargava M, et al. Concurrent methylation of multiple genes in childhood ALL: correlation with phenotype and molecular subgroup. Leukemia. 2003;17:1845-1850.
17. Chim CS, Wong AS, Kwong YL. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol. 2003;82:738-742.
18. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancerrelated genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492-2498.
19. Matsushita C, Yang Y, Takeuchi S, et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in relapsed childhood acute lymphoblastic leukemia. Oncol Rep. 2004;12:97-99.
20. Lemos JA, Defavery R, Scrideli CA, Tone LG. Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias. Sao Paulo Med J. 2003;121:58-62.
21. Kawamura M, Ohnishi H, Guo SX, et al. Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leukemia Res. 1999;23:115-126.
22. Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86:755-760.
23. Rasool O, Heyman M, Brandter LB, et al. p15ink4B and p16ink4 gene inactivation in acute lymphocytic leukemia. Blood. 1995;85:3431-3436.
24. Quesnel B, Preudhomme C, Philippe N, et al. p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood. 1995;85:657-663.
25. Harrison CJ, Martineau M, Secker-Walker LM. The Leukaemia Research Fund/United Kingdom Cancer Cytogenetics Group karyotype database in acute lymphoblastic leukaemia: a valuable resource for patient management. Br J Haematol. 2001;113:3-10.
26. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
27. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
28. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number detection using highdensity oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res. 2005; 65:6071-6079.
29. Strefford JC, van Delft FW, Robinson HM, et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci U S A. 2006;103:8167-8172.
30. Barrett MT, Scheffer A, Ben-Dor A, et al. Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A. 2004;101:17765-17770.
31. Strefford JC, Worley H, Barber K, et al. Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene. 2007;26:4306-4318.
32. Jalali GR, An Q, Konn ZJ, et al. Disruption of ETV6 in intron 2 results in upregulatory and insertional events in childhood acute lymphoblastic leukaemia. Leukemia. 2007;22:114-123.
33. Akasaka T, Balasas T, Russell LJ, et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2007;109:3451-3461.
34. Metaxa-Mariatou V, Papadopoulos S, Papadopoulou E, et al. Molecular analysis of GISTs: evaluation of sequencing and dHPLC. DNA Cell Biol. 2004;23:777-782.
35. Yarbrough WG, Buckmire RA, Bessho M, Liu ET. Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors. J Natl Cancer Inst. 1999;91:1569-1574.
36. Sakano S, Berggren P, Kumar R, et al. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int J Cancer. 2003;104:98-103.
37. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol. 2003;21: 1688-1697.
38. Deligezer U, Erten N, Akisik EE, Dalay N. Methylation of the INK4A/ARF locus in blood mononuclear cells. Ann Hematol. 2006;85:102-107.
39. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446:758-764.
40. Usvasalo A, Savola S, Raty R, et al. CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leukemia Res. 2008;32:1228-1235.
41. Kawamata N, Ogawa S, Zimmermann M, et al. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood. 2008;111:776-784.
42. Mirebeau D, Acquaviva C, Suciu S, et al. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood: results of the EORTC studies 58881 and 58951. Haematologica. 2006;91:881-885.
43. Russell LJ, Akasaka T, Majid A, et al. t(6;14)(p22; q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood. 2008;111:387-391.
44. Teh MT, Blaydon D, Chaplin T, et al. Genomewide single nucleotide polymorphism microarray mapping in basal cell carcinomas unveils uniparental disomy as a key somatic event. Cancer Res. 2005;65:8597-8603.
45. Hu N, Wang C, Hu Y, et al. Genome-wide association study in esophageal cancer using Gene-Chip mapping 10K array. Cancer Res. 2005;65: 2542-2546.
46. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res. 2005;65:375-378.
47. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.
48. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res. 2005;65:9152-9154.
49. Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003;102:2756-2762.
50. Carter TL, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood. 2001;97:572-574.
51. Ramakers-van Woerden NL, Pieters R, Slater RM, et al. In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia. Br J Haematol. 2001;112:680-690.
52. Dalle JH, Fournier M, Nelken B, et al. p16INK4a immunocytochemical analysis is an independent prognostic factor in childhood acute lymphoblastic leukemia. Blood. 2002;99:2620-2623.
53. Zhou M, Gu L, Yeager AM, Findley HW. Incidence and clinical significance of CDKN2/MTS1/ P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1997;14:141-150.
54. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 1995;85:2685-2690.
55. van Zutven LJ, van Drunen E, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastic leukaemia. Leukemia. 2005;19:1281-1284.
56. Graf Einsiedel H, Taube T, Hartmann R, et al. Deletion analysis of p16INKa and p15INKb in relapsed childhood acute lymphoblastic leukemia. Blood. 2002;99:4629-4631.
57. Heerema NA, Sather HN, Sensel MG, et al. Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 1999;94:1537-1544.
58. Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol. 2001;113:103-114.